Humalog (insulin lispro)
- Region
- 🇪🇺 EU
- Active substance
- insulin lispro
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- EU approval
- Tue 30 Apr 1996
- Application
- EMEA/H/C/000088
- ATC
- A10AB04;A10AD04
- Official record
- www.ema.europa.eu
Indication
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bysumlog Authorised · Sandoz GmbH
- 🇪🇺 Lyumjev (previously Liumjev) Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Insulin lispro Sanofi Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Liprolog Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Liprolog Withdrawn · Eli Lilly and Company Limited
Follow Humalog
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.